BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Venetoclax readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Venetoclax\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05053659-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05053659)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Loncastuximab Tesirine and Veneto
 clax for Relapsed/ Refractory Non-Hodgkin Lymphoma\nEstimated primary comp
 letion: November 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05053659
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03980171-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03980171)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Study of Lenalidomide\, Venetoc
 lax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
 \nEstimated primary completion: November 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03980171
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03850574-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03850574)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clinic
 al Trial to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Phar
 macodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refracto
 ry Acute Myeloid Leukemia\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03850574
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895436-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04895436)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: St
 udy to Assess Change in Disease Activity and Adverse Events of Oral Veneto
 clax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurri
 ng Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0489
 5436
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06152809-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06152809)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: CIML NK 
 Cells With Venetoclax for AML\nEstimated primary completion: 30 November 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06152809
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06429449-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06429449)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Mitoxant
 rone for Venetoclax Resistant Acute Myeloid Leukemia\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06429449
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044544-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07044544)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Trial of
  Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignan
 cies\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07044544
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783790-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06783790)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Avapriti
 nib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed 
 AML After Allo-HSCT\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06783790
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03467867-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03467867)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refracto
 ry CLL\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03467867
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955261-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05955261)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Venetoclax in Combination With Conventional Chemotherapy in Pediatric P
 atients With Acute Myeloid Leukemia\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059552
 61
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757855-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06757855)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Olverembatinib Combined With Ve
 netoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML\nEstima
 ted primary completion: 1 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06757855
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05360160-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05360160)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e I-II Study Investigating the All-Oral Combination of the Menin Inhibitor
  SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute 
 Myeloid Leukemia (SAVE)\nEstimated primary completion: 1 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05360160
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06387121-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06387121)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Efficacy and Safety of Low-dose C
 hemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL\
 nEstimated primary completion: 1 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06387121
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05376111-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05376111)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Study of Venetoclax Combined With
  Azacitidine Regimen in Newly Diagnosed T-ALL Patients\nEstimated primary 
 completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05376111
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06220162-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06220162)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VAC Regi
 men for AML Patients Who Failed to Response to VA Regimen\nEstimated prima
 ry completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06220162
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06635681-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06635681)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficacy
  of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups
  of AML\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06635681
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712848-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07712848)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: DEC3-VEN
  vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML\nEstimated pr
 imary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07712848
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04588922-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04588922)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study 
 of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Pa
 tients With Hematologic Malignancies and High-Risk Newly Diagnosed AML\nEs
 timated primary completion: 30 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04588922
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284486-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06284486)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Mult
 i-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhib
 ition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and
  Revumenib\nEstimated primary completion: 30 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06284486
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06451861-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06451861)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Randomiz
 ed Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy 
 or AB-14 for ND AML\nEstimated primary completion: 30 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06451861
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471738-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06471738)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Combination of Zanubrutinib\, Rit
 uximab and Venetoclax in Patients With Previously Untreated Follicular Lym
 phoma\nEstimated primary completion: 30 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06471738
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264010-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07264010)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Sorafe
 nib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML:
  a Prospective\, Single-arm\, Multicenter Clinical Study\nEstimated primar
 y completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07264010
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04161248-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT04161248)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Phase I Master Protocol of Novel 
 Combination Therapy for Patients With Relapsed or Refractory Aggressive B-
 Cell Lymphoma\nEstimated primary completion: 31 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04161248
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010772-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05010772)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Decitabi
 ne Alone or in Combination With Venetoclax\, Gilteritinib\, Enasidenib\, o
 r Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leu
 kemia in Remission\nEstimated primary completion: 31 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05010772
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06621212-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06621212)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Mitoxant
 rone Hydrochloride Liposome\, Standard-dose of Cytarabine and Venetoclax i
 n the Treatment of R/R AML\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06621212
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03513562-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03513562)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax and Ibrutinib in Treating in Participants With Chronic Lymphocyti
 c Leukemia and Ibrutinib Resistance Mutations\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03513562
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06466122-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06466122)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Pi
 rtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With C
 LL or SLL Resistant to Covalent BTKi\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 466122
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05074355-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05074355)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Study of Venetoclax and Azacitidi
 ne in Advanced BCR-ABL Negative Myeloproliferative Neoplasms\nEstimated pr
 imary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05074355
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04216524-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04216524)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Venetoclax\, SL-401\, and Chemoth
 erapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04216524
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03629171-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03629171)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Liposome
 -encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participa
 nts With Relapsed\, Refractory or Untreated Acute Myeloid Leukemia\nEstima
 ted primary completion: 31 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03629171
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04128501-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04128501)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post
 -Transplant Setting\nEstimated primary completion: 31 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04128501
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990321-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06990321)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Effectiv
 eness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation
  Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid 
 Leukemia\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06990321
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486479-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07486479)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax\, Azacitidine\, and Mitoxantrone Hydrochloride Liposome Versus Idarubic
 in and Cytarabine in Newly Diagnosed AML\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venet
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07486479
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04790045-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Venetoclax: Phase 4 readout est. (NCT04790045)
DESCRIPTION:Venetoclax\, phase 4\, Chronic Lymphocytic Leukemia.\nStudy: Ly
 mph Node Microenvironment Modifications in Patients With CLL Treated With 
 Venetoclax-based Regimens\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04790045
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317403-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05317403)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax to Augment Epigenetic Modification and Chemotherapy\nEstimated primary 
 completion: January 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05317403
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03826992-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 1 readout est. (NCT03826992)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Venetoclax Combined With Vyxeos (
 CPX-351) for Participants With Relapsed or Refractory Acute Leukemia\nEsti
 mated primary completion: January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03826992
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05001828-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05001828)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Study of
  ADI-PEG 20\, Venetoclax and Azacitidine in Acute Myeloid Leukemia\nEstima
 ted primary completion: January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05001828
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177067-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06177067)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Study of
  Revumenib\, Azacitidine\, and Venetoclax in Pediatric and Young Adult Pat
 ients With Refractory or Relapsed Acute Myeloid Leukemia\nEstimated primar
 y completion: January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06177067
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773208-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06773208)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06773208
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384261-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06384261)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Az
 acitidine in Newly Diagnosed AML Ineligible for Intensive Therapy\nEstimat
 ed primary completion: January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06384261
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04801797-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04801797)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax + Azacitidine vs. Induction Chemotherapy in AML\nEstimated primary comp
 letion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04801797
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06763341-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06763341)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 
 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leuk
 emia\nEstimated primary completion: 16 January 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06763341
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03862157-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03862157)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azacit
 idine\, Venetoclax\, and Pevonedistat in Treating Patients With Newly Diag
 nosed Acute Myeloid Leukemia\nEstimated primary completion: 31 January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03862157
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541755-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07541755)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: PD-1 Inhibitors +Venetoclax+CAG R
 egimens in R/R T-ALL\nEstimated primary completion: 31 January 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07541755
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04086264-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04086264)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: IMGN63
 2 as Monotherapy or With Venetoclax and/or Azacitidine for Participants Wi
 th CD123-Positive Acute Myeloid Leukemia\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4086264
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04515238-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04515238)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Sequential Regimen of Bendamustin
 e Followed by Obinutuzumab (GA101)\, Zanubrutinib (BGB-3111) and Venetocla
 x (ABT-199) in Patients With Relapsed/Refractory CLL\nEstimated primary co
 mpletion: February 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04515238
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03824483-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03824483)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: St
 udy of Zanubrutinib\, Obinutuzumab\, and Venetoclax in Patients With Chron
 ic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)\nEstimat
 ed primary completion: February 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03824483
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183035-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05183035)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax in Children With Relapsed Acute Myeloid Leukemia (AML)\nEstimated prima
 ry completion: February 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05183035
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06399640-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06399640)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Eltanexo
 r and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Ac
 ute Myeloid Leukemia\nEstimated primary completion: 1 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06399640
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05861050-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05861050)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Glofitamab With Obinutuzumab\, 
 Venetoclax\, and Lenalidomide for the Treatment of Patients With Newly Dia
 gnosed High Risk Mantle Cell Lymphoma\nEstimated primary completion: 1 Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 861050
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05391750-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05391750)
DESCRIPTION:Venetoclax\, phase 1\, Multiple Myeloma.\nStudy: Venetoclax and
  Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(1
 1\;14) Multiple Myeloma\nEstimated primary completion: 12 February 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05391750
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04939272-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04939272)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Copanlisib and Venetoclax for t
 he Treatment of Relapsed or Refractory Mantle Cell Lymphoma\nEstimated pri
 mary completion: 12 February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04939272
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02846623-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02846623)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: At
 ezolizumab\, Obinutuzumab\, and Venetoclax in Treating Patients With Chron
 ic Lymphocytic Leukemia\, Small Lymphocytic Lymphoma\, or Relapsed or Refr
 actory Richter Syndrome\nEstimated primary completion: 28 February 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT02846623
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06522386-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06522386)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: GATE1: A Multicenter Phase II Stu
 dy of Pirtobrutinib\, Rituximab and Venetoclax Combination Therapy for Pat
 ients With Previously Untreated Mantle Cell Lymphoma\nEstimated primary co
 mpletion: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06522386
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428969-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05428969)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stud
 y to Assess Safety\, Tolerability and Preliminary Efficacy of Bexmarilimab
  in Combination With Standard of Care in Patients With Hematological Malig
 nancies\nEstimated primary completion: March 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05428969
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06129734-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06129734)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Decita
 bine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allo
 graft Stem Cell Transplant\nEstimated primary completion: March 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06129734
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05650723-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05650723)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Za
 nubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leuke
 mia (CLL) With Response-based Obinutuzumab\nEstimated primary completion: 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 650723
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05668026-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05668026)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Administration of Venetoclax to
  Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Re
 servoir Among People Living With HIV on ART\nEstimated primary completion:
  1 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/veneto
 clax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05668026
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05222984-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270302
DTEND;VALUE=DATE:20270303
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05222984)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Navitocl
 ax\, Venetoclax\, and Decitabine for the Treatment of Relapsed or Refracto
 ry Acute Myeloid Leukemia Previously Treated With Venetoclax\nEstimated pr
 imary completion: 2 March 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05222984
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357182-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06357182)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Iadadems
 tat in Combination With Azacitidine and Venetoclax in Treating Newly Diagn
 osed Acute Myeloid Leukemia\nEstimated primary completion: 8 March 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06357182
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03710772-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03710772)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Ibrutinib\, Rituximab\, Venetocla
 x\, and Combination Chemotherapy in Treating Patients With Newly Diagnosed
  Mantle Cell Lymphoma\nEstimated primary completion: 22 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03710772
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287568-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05287568)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: CC-486 a
 nd Venetoclax for Acute Myeloid Leukemia\nEstimated primary completion: 23
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5287568
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study 
 to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated 
 primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554406-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05554406)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagn
 osed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)\nEs
 timated primary completion: 31 March 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05554406
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672146-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06672146)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Comparin
 g New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia Th
 at Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06672146
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05853965-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05853965)
DESCRIPTION:Venetoclax\, phase 1/2\, Multiple Myeloma.\nStudy: Combination 
 Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed 
 and Refractory t(11\;14) Multiple Myeloma\nEstimated primary completion: A
 pril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 53965
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04450173-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04450173)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Obinutuzumab\, Ibrutinib\, and Ve
 netoclax for the Treatment of Previously Untreated Stage II-IV Follicular 
 Lymphoma\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04450173
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847957-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07847957)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL\nEstimated primary c
 ompletion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07847957
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012447-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07012447)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Venetoclax + Azacytidine for Newl
 y Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations\nEstimated prima
 ry completion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07012447
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537257-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07537257)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: VEN+ID
 AC vs IDAC in AML\nEstimated primary completion: 1 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07537257
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05157971-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05157971)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Venetoclax and a Pediatric-Inspir
 ed Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic
  Leukemia\nEstimated primary completion: 12 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05157971
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05529069-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05529069)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Phase II Study of Pirtobrutinib W
 ith Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients\
 nEstimated primary completion: 28 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05529069
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03586609-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03586609)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax\, Cladribine\, Low Dose Cytarabine\, and Azacitidine in Treating Patien
 ts With Previously Untreated Acute Myeloid Leukemia\nEstimated primary com
 pletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03586609
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: St
 udy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)\, 
 With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previo
 usly Untreated CLL\nEstimated primary completion: 30 April 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05386576-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05386576)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: A Study of Venetoclax in Combinat
 ion With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemi
 a (ALL)\nEstimated primary completion: May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05386576
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04419519-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04419519)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: As
 sessing Minimal Residual Disease by Next- Generation Sequencing to Minimiz
 e Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
 \nEstimated primary completion: May 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04419519
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07921550-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Venetoclax: Phase na readout est. (NCT07921550)
DESCRIPTION:Venetoclax\, phase na.\nStudy: Venetoclax Plus Inotuzumab Reduc
 ed-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL\nEst
 imated primary completion: 1 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07921550
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04150887-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Venetoclax: Phase 1 readout est. (NCT04150887)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Cusatuzu
 mab in Combination With Background Therapy for the Treatment of Participan
 ts With Acute Myeloid Leukemia\nEstimated primary completion: 15 May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04150887
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311227-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06311227)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Venetoclax for the Treatment of P
 atients With Relapsed Hairy Cell Leukemia\nEstimated primary completion: 2
 0 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 311227
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03128879-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03128879)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL\nEstim
 ated primary completion: 31 May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03128879
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975919-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04975919)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax in Combination With Decitabine and Cedazuridine for the Treatment of Re
 lapsed or Refractory Acute Myeloid Leukemia\nEstimated primary completion:
  31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04975919
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05986240-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05986240)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Danvatir
 sen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refrac
 tory MDS & AML\nEstimated primary completion: June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05986240
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02899052-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02899052)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: Study of Venet
 oclax in Combination With Carfilzomib and Dexamethasone in Participants Wi
 th Relapsed or Refractory Multiple Myeloma (MM)\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venet
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT02899052
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04416451-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04416451)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: A Phase II Study Using Rituximab 
 Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma\nEst
 imated primary completion: June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04416451
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07199855-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07199855)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Blinatumomab Combined With Veneto
 clax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute
  B-cell Lymphoblastic Leukemia\nEstimated primary completion: 1 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07199855
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032727-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07032727)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Olutasidenib Combined With Co-tar
 geted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies 
 Harboring Activated Signaling Pathway Mutations\nEstimated primary complet
 ion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ven
 etoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07032727
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03523975-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270624
DTEND;VALUE=DATE:20270625
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03523975)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Venetoclax\, Lenalidomide and R
 ituximab in Patients With Previously Untreated Mantle Cell Lymphoma\nEstim
 ated primary completion: 24 June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03523975
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03041688-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 1 readout est. (NCT03041688)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Testing 
 a New Chemotherapy Drug\, KRT-232 (AMG-232) in Combination With Decitabine
  and Venetoclax in Patients With Acute Myeloid Leukemia\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03041688
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04855695-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04855695)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Avo In R/R And Previously Untre
 ated MCL\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04855695
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988555-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horiz
 en-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445959-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06445959)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Phase 1b/2 Study of Decitabine 
 and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olut
 asidenib\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06445959
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06429098-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06429098)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study of
  A Venetoclax-based\, Anthracycline-free Regimen in Newly Diagnosed CBFβ:
 :MYH11(+) AML\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06429098
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06372717-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06372717)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study 
 to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06372717
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04447768-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04447768)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Th
 e Combination of Venetoclax and Obinutuzumab in People With Chronic Lympho
 cytic Leukemia (CLL)\nEstimated primary completion: July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04447768
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04401748-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04401748)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: Study Of Venetoclax Tablet With I
 ntravenous or Subcutaneous Azacitidine to Assess Change in Disease Activit
 y In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic S
 yndrome\nEstimated primary completion: July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04401748
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06090786-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Venetoclax: Phase na readout est. (NCT06090786)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Kinetic
 s and Impact on Survival of MRD in AML Patients Receiving Azacitidine and 
 Venetoclax\nEstimated primary completion: July 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06090786
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445907-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06445907)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Phase I 
 Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory A
 cute Myeloid Leukemia\nEstimated primary completion: 1 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06445907
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02756897-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02756897)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocy
 tic Leukemia\nEstimated primary completion: 1 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02756897
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187505-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Venetoclax: Phase na readout est. (NCT07187505)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leuk
 emia\nEstimated primary completion: 1 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07187505
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04227847-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270704
DTEND;VALUE=DATE:20270705
SUMMARY:Venetoclax: Phase 1 readout est. (NCT04227847)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Safety
  Study of SEA-CD70 in Patients With Myeloid Malignancies\nEstimated primar
 y completion: 4 July 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04227847
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06496308-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06496308)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: Bendamustine and Rituximab With o
 r Without Orelabrutinib in MCL Treatment\nEstimated primary completion: 10
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 496308
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab
  in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic
  Lymphoma\nEstimated primary completion: 15 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191263-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06191263)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Safety a
 nd Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/R
 efractory AML\nEstimated primary completion: August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06191263
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214064-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07214064)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allog
 eneic Stem Cell Transplantation\nEstimated primary completion: August 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07214064
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844048-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03844048)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Exten
 sion Study of Venetoclax for Subjects Who Have Completed a Prior Venetocla
 x Clinical Trial\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03844048
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532552-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06532552)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Comparis
 on of VA (Venetoclax\, Azacitidine)\, VACl (VA\, Cladribine)\, VACh (VA\, 
 Chidamide)\, and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Le
 ukemia\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06532552
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651229-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270805
DTEND;VALUE=DATE:20270806
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06651229)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study 
 of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelo
 dysplastic Neoplasms\nEstimated primary completion: 5 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06651229
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04941716-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04941716)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ac
 alabrutinib in Combination With Venetoclax for the Treatment of Refractory
  or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\,
  The AVENUE-2 Trial\nEstimated primary completion: 10 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04941716
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03223610-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03223610)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Venetoclax\, Ibrutinib\, Predni
 sone\, Obinutuzumab\, and Revlimid (ViPOR) in Relapsed/Refractory B-cell L
 ymphoma\nEstimated primary completion: 12 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03223610
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183878-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Venetoclax: Phase na readout est. (NCT07183878)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Venetoc
 lax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS 
 Patients Undergoing Allo-HSCT (Ven-BUCY Study)\nEstimated primary completi
 on: 20 August 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 enetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07183878
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132684-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07132684)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Comparis
 on of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia
  Patients\nEstimated primary completion: 30 August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07132684
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712121-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06712121)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Venetoclax and Decitabine in R/R 
 T-ALL\nEstimated primary completion: 31 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06712121
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05600894-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05600894)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Venetoclax in Combination With AS
 TX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelo
 dysplastic Syndrome/Myeloproliferative Neoplasm\nEstimated primary complet
 ion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05600894
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07451912-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07451912)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mut
 ated AML\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07451912
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451771-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05451771)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Venetoclax-Dexamethasone in Rel
 apsed and/or Refractory t(11\;14) Amyloidosis\nEstimated primary completio
 n: September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05451771
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07726576-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07726576)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid
  Leukemia\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07726576
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04608318-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04608318)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: Ibrutinib Monotherapy Versus Fixe
 d-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Pl
 us Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Le
 ukaemia (CLL)\nEstimated primary completion: September 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04608318
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743112-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07743112)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 
 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit New
 ly Diagnosed Acute Myeloid Leukemia\nEstimated primary completion: 1 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 43112
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722767-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07722767)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 
 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML 
 Patients\nEstimated primary completion: 30 September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07722767
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03471260-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03471260)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Ivosid
 enib and Venetoclax With or Without Azacitidine in Treating Patients With 
 IDH1 Mutated Hematologic Malignancies\nEstimated primary completion: 30 Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03471260
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03214562-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03214562)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax With Combination Chemotherapy in Treating Patients With Newly Diagnos
 ed or Relapsed or Refractory Acute Myeloid Leukemia\nEstimated primary com
 pletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03214562
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05401097-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05401097)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: IDH Targ
 eted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatmen
 t of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive
  Induction Therapy (I- DATA Study)\nEstimated primary completion: 30 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 01097
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514936-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07514936)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients
  With Acute Myeloid Leukaemia\nEstimated primary completion: 30 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07514936
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06634394-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06634394)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: APVO436 
 Phase 1b/2 Study in Patients With Newly Diagnosed AML\nEstimated primary c
 ompletion: October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06634394
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486726-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07486726)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Aclaru
 bicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myelo
 id Leukemia\nEstimated primary completion: October 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07486726
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06511882-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06511882)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Disconti
 nuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD\n
 Estimated primary completion: October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06511882
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163793-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07163793)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Pilot St
 udy of Reduced Venetoclax Exposure\nEstimated primary completion: October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07163793
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374029-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07374029)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Adoptive
  T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax 
 in AML\nEstimated primary completion: 1 October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07374029
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07632170-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Venetoclax: Phase na readout est. (NCT07632170)
DESCRIPTION:Venetoclax\, phase na.\nStudy: The Efficacy and Safety of Selin
 isole Combined With Azacitidine and Venetoclax in the Treatment of Newly D
 iagnosed High-risk Myeloid Tumors With TP53 Mutations\nEstimated primary c
 ompletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07632170
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504459-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06504459)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax in Combination With Cladribine and Cytarabine Alternating With Azacitid
 ine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and
  Active Signaling Mutated AML\nEstimated primary completion: 11 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06504459
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686108-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06686108)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Demethylating Agents Combined Wit
 h Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Tra
 nsplant Relapse Prevention\nEstimated primary completion: 30 October 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06686108
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02250937-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02250937)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax and Sequential Busulfan\, Cladribine\, and Fludarabine Phosphate Before
  Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Le
 ukemia or Myelodysplastic Syndrome\nEstimated primary completion: 31 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02250
 937
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660368-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06660368)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: BCL2i CL
 AG-M in R/R Acute Myeloid Leukemia\nEstimated primary completion: November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0666036
 8
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044687-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Venetoclax: Phase 4 readout est. (NCT07044687)
DESCRIPTION:Venetoclax\, phase 4\, Acute Myeloid Leukemia.\nStudy: Study to
  Assess Adverse Events and Change in Disease Activity of Oral Venetoclax i
 n Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Ne
 wly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are
  Ineligible for Standard Induction Therapy in India\nEstimated primary com
 pletion: November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07044687
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04256317-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT04256317)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Mult
 i-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplas
 m Alone or in Combination With Venetoclax in AML (AZTOUND Study)\nEstimate
 d primary completion: 1 November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04256317
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917911-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271125
DTEND;VALUE=DATE:20271126
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06917911)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatmen
 t Regimen (Cytarabine and Daunorubicin\, "7+3") for Core Binding Factor Ac
 ute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment
  Trial)\nEstimated primary completion: 25 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06917911
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03331198-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03331198)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed 
 or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymp
 homa (SLL)\nEstimated primary completion: 26 November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03331198
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774393-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04774393)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Decita
 bine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enaside
 nib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia\nEs
 timated primary completion: 29 November 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04774393
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04581512-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04581512)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study 
 to Evaluate the Safety and Tolerability of EP0042\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04581512
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refract
 ory Chronic Lymphocytic Leukemia and Richter's Syndrome\nEstimated primary
  completion: December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04623541
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470841-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06470841)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: CHG Comb
 ined With Venetoclax and Azacytidine in Newly Diagnosed AML\nEstimated pri
 mary completion: December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06470841
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02781883-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02781883)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clinical
  Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AM
 L\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02781883
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06390319-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06390319)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Adding Dasatinib Or Venetoclax To
  Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphobla
 stic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia 
 (MPAL)\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06390319
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255872-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07255872)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax 
 + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07255872
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548230-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06548230)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without
  Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Mye
 logenous Leukemia (AML)\nEstimated primary completion: 1 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06548230
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958705-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06958705)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monot
 herapy\nEstimated primary completion: 1 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06958705
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744556-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06744556)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: HAV Vers
 us DAV/IAV Induction Regimen in Elderly Patients With AML\nEstimated prima
 ry completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06744556
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04872790-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Venetoclax: Phase 1 readout est. (NCT04872790)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Venetoclax\, Dasatinib\, Predniso
 ne\, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Re
 lapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mi
 xed Phenotype Acute Leukemia\nEstimated primary completion: 2 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04872790
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844815-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Venetoclax: Phase 1 readout est. (NCT03844815)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Study of
  Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid 
 Leukemia\nEstimated primary completion: 10 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03844815
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05660473-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05660473)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Pediatric-inspired Regimen Combin
 ed With Venetoclax for Adolescent and Adult Patients With de Novo Philadel
 phia Chromosome-Negative Acute Lymphoblastic Leukemia\nEstimated primary c
 ompletion: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05660473
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05963074-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05963074)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study to Customize Ibrutinib Treatment Regimens for Participants With Prev
 iously Untreated Chronic Lymphocytic Leukemia\nEstimated primary completio
 n: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05963074
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06571825-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Venetoclax: Phase 4 readout est. (NCT06571825)
DESCRIPTION:Venetoclax\, phase 4\, Acute Myeloid Leukemia.\nStudy: RIC Allo
 -HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After Fir
 st CR\nEstimated primary completion: 30 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06571825
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06232694-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Venetoclax: Phase na readout est. (NCT06232694)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Clinica
 l Study Protocol of IAV-induced Remission Followed by Consolidation Therap
 y With MDCyta+Ven in ND-AML\nEstimated primary completion: 30 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06232694
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06328179-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Venetoclax: Phase na readout est. (NCT06328179)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Clinica
 l Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Ab
 normalities Using VHEA.\nEstimated primary completion: 30 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06328179
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06386302-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Venetoclax: Phase na readout est. (NCT06386302)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Chidami
 de\, Venetoclax\, and Azacitidine for Newly Diagnosed Acute Myeloid Leukem
 ia\nEstimated primary completion: 30 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06386302
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03874052-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT03874052)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Ruxoliti
 nib in Combination With Venetoclax With and Without Azacitidine in Treatin
 g Patients With Relapsed or Refractory Acute Myeloid Leukemia\nEstimated p
 rimary completion: 31 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03874052
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06466395-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06466395)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: A Phase I Study of Hyper-CVAD In 
 Combination With Venetoclax In Pediatric Patients With Relapsed or Refract
 ory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotyp
 ic or Undifferentiated Leukemias\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064663
 95
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828535-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07828535)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Liposoma
 l Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly 
 or Unfit AML\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07828535
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04797767-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04797767)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade
  Myeloid Neoplasms\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04797767
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06621199-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06621199)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Mitoxant
 rone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax 
 Regimen in Newly Diagnosed Elderly AML\nEstimated primary completion: 31 D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06621199
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05365035-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05365035)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: A Phase II Study of Cladribine an
 d Low Dose Cytarabine in Combination With Venetoclax\, Alternating With Az
 acitidine and Venetoclax\, in Patients With Higher-risk Myeloproliferative
  Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes 
 With Excess Blasts\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05365035
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748455-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07748455)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: HMA-Vene
 toclax Induction in Newly Diagnosed AML\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/veneto
 clax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07748455
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862517-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07862517)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 the Investigational Medication Combination of Azacitidine\, Venetoclax\, a
 nd Quizartinib Compared to the Usual Treatment of Cytarabine\, Daunorubici
 n\, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukem
 ia (A MyeloMATCH Treatment Trial)\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07862
 517
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557056-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07557056)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ne
 mtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymp
 hocytic Leukemia or Small Lymphocytic Lymphoma\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07557056
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554393-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05554393)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Comparin
 g Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Ven
 etoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermedi
 ate Risk AML (A MyeloMATCH Treatment Trial)\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05554393
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734038-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07734038)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukem
 ia and Small Lymphocytic Lymphoma\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07734
 038
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052422-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07052422)
DESCRIPTION:Venetoclax\, phase 2/3.\nStudy: VEN+DAC+Bu2Flu4 vs Bu2Flu5 Cond
 itioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07052422
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04708054-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT04708054)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With
  High-Risk AML and MDS\nEstimated primary completion: 31 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04708054
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392242-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07392242)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of the Combination of Ivosidenib\, Azacitidine\, and Venetoclax Followed b
 y Ivosidenib Alone in People With Acute Myeloid Leukemia\nEstimated primar
 y completion: January 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07392242
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863259-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06863259)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Study of Inotuzumab Ozogamicin\, 
 Venetoclax\, and Dexamethasone for Relapsed B-cell ALL\nEstimated primary 
 completion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06863259
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03661307-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT03661307)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Quizar
 tinib\, Decitabine\, and Venetoclax in Treating Participants With Untreate
 d or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
 \nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03661307
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243483-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Venetoclax: Phase na readout est. (NCT07243483)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Study o
 f the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics 
 of Venetoclax in Patients With Acute Myeloblastic Leukemia\nEstimated prim
 ary completion: 1 January 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07243483
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010122-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05010122)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: ASTX72
 7\, Venetoclax\, and Gilteritinib for the Treatment of Newly Diagnosed\, R
 elapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Mye
 lodysplastic Syndrome\nEstimated primary completion: 30 January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05010122
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265545-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Venetoclax: Phase na readout est. (NCT06265545)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Multice
 nter\, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid 
 Leukemia\nEstimated primary completion: 30 January 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265545
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07439211-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07439211)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Assessin
 g PI3K Gamma Inhibition With Azacitidine\, Venetoclax and Eganelisib in Pa
 tients With Acute Myeloid Leukemia\nEstimated primary completion: 1 Februa
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07439
 211
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407660-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07407660)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Shortene
 d Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in
  Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus
  Venetoclax\nEstimated primary completion: 1 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07407660
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03946878-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03946878)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Venetoclax and Acalabrutinib in T
 reating Patients With Relapsed or Refractory Mantle Cell Lymphoma\nEstimat
 ed primary completion: 8 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03946878
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456463-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06456463)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults Wi
 th Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Ch
 emotherapy\nEstimated primary completion: 9 February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06456463
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201066-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05201066)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Roll-over Study for Patients Who 
 Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and A
 re Judged by the Investigator to Benefit From Continued Treatment With Sab
 atolimab.\nEstimated primary completion: 14 February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05201066
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05099471-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05099471)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Efficacy of Venetoclax in Combina
 tion With Rituximab in Waldenström's Macroglobulinemia\nEstimated primary
  completion: March 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05099471
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Particip
 ants Receiving Oral Venetoclax in Combination With Intravenously Infused O
 binutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphoc
 ytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04560322-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04560322)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL\nEstimated primary comp
 letion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04560322
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454226-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Venetoclax: Phase na readout est. (NCT07454226)
DESCRIPTION:Venetoclax\, phase na.\nStudy: ABL/JAK Inhibitors With Chemothe
 rapy and Venetoclax for Ph-like ALL\nEstimated primary completion: 1 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0745422
 6
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07495631-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Venetoclax: Phase na readout est. (NCT07495631)
DESCRIPTION:Venetoclax\, phase na.\nStudy: Pediatric-Inspired Regimen Combi
 ned With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphobl
 astic Leukemia\nEstimated primary completion: 1 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07495631
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05530421-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280326
DTEND;VALUE=DATE:20280327
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05530421)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: Selinexor\, Ve
 netoclax\, and Dexamethasone (XVenD) in t(11\;14)-Positive Relapsed/Refrac
 tory Multiple Myeloma\nEstimated primary completion: 26 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05530421
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507825-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07507825)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Explorat
 ory Study of Venetoclax\, Homoharringtonine\, Azacitidine Plus G-CSF for N
 ewly Diagnosed AML (VHAG)\nEstimated primary completion: 31 March 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07507825
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783100-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07783100)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax\, Chidamide\, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Re
 fractory Acute Myeloid Leukemia\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07783100
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04840602-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04840602)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Testing the Combination of Veneto
 clax and Rituximab\, in Comparison to the Usual Treatment (Ibrutinib Plus 
 Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymph
 oplasmacytic Lymphoma\nEstimated primary completion: 31 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04840602
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469046-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07469046)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAH vs V
 A in Newly Diagnosed Elderly AML\nEstimated primary completion: 31 March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07469046
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493161-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase na readout est. (NCT07493161)
DESCRIPTION:Venetoclax\, phase na.\nStudy: Chemotherapy With Targeted-Immun
 otherapy for Newly Diagnosed Ph+ ALL\nEstimated primary completion: 31 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07493
 161
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018752-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07018752)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: A Platform Trial Evaluating New
  Drugs or Combination in R/R Peripheral T-cell Lymphomas\nEstimated primar
 y completion: April 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07018752
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514832-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07514832)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA-CIG R
 egimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Pros
 pective Single-Arm Trial\nEstimated primary completion: 1 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07514832
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231952-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280411
DTEND;VALUE=DATE:20280412
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07231952)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: A Study of Pirtobrutinib\, Veneto
 clax\, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/
 Lymphoplasmacytic Lymphoma (LPL)\nEstimated primary completion: 11 April 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07231952
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536349-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280425
DTEND;VALUE=DATE:20280426
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05536349)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ti
 me-limited Triplet Combination of Pirtobrutinib\, Venetoclax\, and Obinutu
 zumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL
 ) or Richter Transformation (RT)\nEstimated primary completion: 25 April 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05536349
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283094-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07283094)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: FHD-286 
 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid 
 Leukemia\nEstimated primary completion: May 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07283094
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06558604-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06558604)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Phase II Study of Glofitamab With
  Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma\nEstimated 
 primary completion: May 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06558604
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05197192-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05197192)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Phase-3-trial of Acalabrutinib\, Obinutuzumab & Venetoclax Compared to Obi
 nutuzumab and Venetoclax in Previously Untreated Patients With High Risk C
 LL\nEstimated primary completion: May 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05197192
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701282-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280507
DTEND;VALUE=DATE:20280508
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03701282)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: As
 sessing the Ability of Combination Treatment With Venetoclax to Permit Tim
 e Limited Therapy in Chronic Lymphocytic Leukemia\nEstimated primary compl
 etion: 7 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03701282
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131059-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Venetoclax: Phase na readout est. (NCT07131059)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: MRD-pos
 itive AML Clinical Study\nEstimated primary completion: 10 May 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07131059
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954987-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06954987)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoi
 etic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Ther
 apy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH
  Treatment Trial)\nEstimated primary completion: 15 May 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06954987
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643103-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07643103)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Immuno-Targeted Therapy Plus Low-
 Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospecti
 ve Umbrella Trial\nEstimated primary completion: 31 May 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07643103
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664839-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07664839)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study on
  the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly 
 Diagnosed AML With NPM1 or IDH1/IDH2 Mutations\nEstimated primary completi
 on: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vene
 toclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07664839
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840976-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07840976)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Immunotargeted Therapy Plus Low-D
 ose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL\nEstimated primary com
 pletion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07840976
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814339-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07814339)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Hydrochl
 oroquinine & Decitabine With Venetoclax in AML\nEstimated primary completi
 on: June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/veneto
 clax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07814339
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668558-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06668558)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax + Azacitidine in Patients With Acute Myeloid Leukemia\nEstimated primar
 y completion: June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06668558
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867626-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07867626)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Phase II
  De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax
  in AML\nEstimated primary completion: June 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07867626
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05404906-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT05404906)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: AZA + 
 Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remi
 ssion\nEstimated primary completion: June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05404906
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133997-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07133997)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Recombinant Erwinia Asparaginase 
 and Venetoclax in Combination With Blinatumomab for the Treatment of Relap
 sed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia\nEstim
 ated primary completion: 1 June 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07133997
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642453-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07642453)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA-CAG T
 wo-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed 
 Acute Myeloid Leukemia.\nEstimated primary completion: 1 June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07642453
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014917-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07014917)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: In
 termittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL\nEs
 timated primary completion: 5 June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07014917
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05834244-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05834244)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 
 Ib Trial of Azacitidine\, Venetoclax and Allogeneic NK Cells for Acute Mye
 loid Leukemia (ADVENT-AML)\nEstimated primary completion: 30 June 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05834244
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04847453-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Venetoclax: Phase 1 readout est. (NCT04847453)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Venetoclax\, MLN9708 (Ixazomib Ci
 trate) and Dexamethasone for the Treatment of Relapsed or Refractory Light
  Chain Amyloidosis\nEstimated primary completion: 30 June 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04847453
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387471-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07387471)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Study to Assess Change in Disease
  Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed
  or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic
  Lymphoma (LPL)\nEstimated primary completion: July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07387471
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605949-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07605949)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Revumeni
 b\, Azacitidine\, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML\n
 Estimated primary completion: July 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07605949
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05292664-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280702
DTEND;VALUE=DATE:20280703
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05292664)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax Basket Trial for High Risk Hematologic Malignancies\nEstimated primary 
 completion: 2 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05292664
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: A Study in Patients Previously En
 rolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizum
 ab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04169737-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280709
DTEND;VALUE=DATE:20280710
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04169737)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ac
 alabrutinib and Venetoclax With or Without Early Obinutuzumab for the Trea
 tment of High Risk\, Recurrent\, or Refractory Chronic Lymphocytic Leukemi
 a or Small Lymphocytic Lymphoma\nEstimated primary completion: 9 July 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04169737
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04655755-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280720
DTEND;VALUE=DATE:20280721
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04655755)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Venetoclax in Combination With 
 ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syn
 drome or Chronic Myelomonocytic Leukemia\nEstimated primary completion: 20
  July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 655755
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07735117-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280720
DTEND;VALUE=DATE:20280721
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07735117)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Mitoxant
 rone Hydrochloride Liposome\, Cytarabine\, G-CSF Plus Venetoclax vs. Azaci
 tidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML\nEstimated pr
 imary completion: 20 July 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07735117
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05520567-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05520567)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stud
 y of Gilteritinib\, Venetoclax and Azacitidine as a Combined Treatment for
  People Newly Diagnosed With Acute Myeloid Leukemia\nEstimated primary com
 pletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05520567
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03984448-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT03984448)
DESCRIPTION:Venetoclax\, phase 2/3.\nStudy: Testing the Addition of a New A
 nti-cancer Drug\, Venetoclax\, to Usual Chemotherapy for High Grade B-cell
  Lymphomas\nEstimated primary completion: 13 August 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03984448
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679334-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07679334)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Phase I Trial of Pacritinib in Co
 mbination With Venetoclax and Azacitidine for the Treatment of Accelerated
  and Blast Phase Myeloproliferative Neoplasms\nEstimated primary completio
 n: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07679334
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140487-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04140487)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Azacit
 idine\, Venetoclax\, and Gilteritinib in Treating Patients With Recurrent/
 Refractory FLT3-Mutated Acute Myeloid Leukemia\, Chronic Myelomonocytic Le
 ukemia\, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
 \nEstimated primary completion: 1 September 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04140487
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159620-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07159620)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Venetoclax Combined With Azacitid
 ine\, Chidamide\, Vindesine\, and Dexamethasone in Newly Diagnosed ETP-ALL
  Like Patients\nEstimated primary completion: 1 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07159620
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649812-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06649812)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Testing the Effectiveness of a Co
 mbination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refra
 ctory Aggressive B-cell Lymphoma\nEstimated primary completion: 1 Septembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066498
 12
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07512700-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07512700)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Venetoclax Combined With CACAG Re
 gimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia\nE
 stimated primary completion: 30 September 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07512700
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059975-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07059975)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: UPDATE A
 ML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Ped
 iatric AML\nEstimated primary completion: October 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07059975
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510309-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06510309)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Rituximab Plus Venetoclax in Fron
 t Line Marginal Zone Lymphoma\nEstimated primary completion: October 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06510309
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644183-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06644183)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapse
 d Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: 1 Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0664
 4183
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06516978-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06516978)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: A Study Comparing the Efficacy an
 d Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreat
 ed Patients With DLBCL\nEstimated primary completion: 1 October 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06516978
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425808-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07425808)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: FLT3-I
 TD Targeted Therapy in Fit AML Patients\nEstimated primary completion: 1 O
 ctober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7425808
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04269902-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04269902)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: Te
 sting Early Treatment for Patients With High-Risk Chronic Lymphocytic Leuk
 emia (CLL) or Small Lymphocytic Leukemia (SLL)\, EVOLVE CLL/SLL Study\nEst
 imated primary completion: 1 October 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04269902
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00501826-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT00501826)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Combination Chemotherapy and Nela
 rabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Ly
 mphoblastic Lymphoma\nEstimated primary completion: 31 October 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT00501826
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05951959-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05951959)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: A Study of Acalabrutinib Plus Ven
 etoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Ly
 mphoma\nEstimated primary completion: 31 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05951959
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04746235-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04746235)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax and ASTX727 for the Treatment of Relapsed\, Refractory\, or Newly Diagn
 osed Acute Myeloid Leukemia\nEstimated primary completion: 31 October 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04746235
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06557421-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06557421)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: De-Escal
 ation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML R
 esponding Patients\nEstimated primary completion: 1 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06557421
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07425782-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281126
DTEND;VALUE=DATE:20281127
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07425782)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax Combined With Azacitidine for Consolidation Therapy in AML\nEstimated p
 rimary completion: 26 November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07425782
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07940621-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07940621)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Inotuzumab Plus Venetoclax in Old
 er or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALL\nEstima
 ted primary completion: 30 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07940621
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05342584-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05342584)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax Plus Intensive Chemotherapy in AML and Advanced MDS\nEstimated primary 
 completion: December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05342584
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221683-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06221683)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clinical
  Study of Induction Therapy Options Based on Molecular Subtyping and MRD i
 n Children and Adolescents With AML\nEstimated primary completion: Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062216
 83
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523428-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04523428)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: REtreatment With VEnetoclax and A
 calabrutinib After Venetoclax Limited Duration (REVEAL)\nEstimated primary
  completion: December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04523428
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06014489-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06014489)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Trial 
 to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in
  Adult Patients With Newly Diagnosed AML\nEstimated primary completion: De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6014489
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060001-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07060001)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Efficacy
  of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leu
 kemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker\nEstimat
 ed primary completion: December 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07060001
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075016-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07075016)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Ivosiden
 ib and Azacitidine With or Without Venetoclax in Adult Patients With Newly
  Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive
  Chemotherapy\nEstimated primary completion: December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07075016
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874100-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase na readout est. (NCT07874100)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: This St
 udy Aims to Improve the Stratification of Patients With Acute Myeloid Leuk
 emia to Enable More Personalized and Effective Treatments\, and to Identif
 y and Functionally Validate\, at the Single-cell Level\, Biomarkers That C
 an Predict Response to Venetoclax.\nEstimated primary completion: December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0787410
 0
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007052-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281210
DTEND;VALUE=DATE:20281211
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07007052)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Phase II Study Evaluating the Eff
 icacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treat
 ment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients\nEstimate
 d primary completion: 10 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07007052
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841952-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Venetoclax: Phase na readout est. (NCT06841952)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: Study o
 f Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Tre
 atment Naïve Participants With Acute Myeloid Leukemia\nEstimated primary 
 completion: 15 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06841952
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448013-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06448013)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 
 I Study Investigating the Combination of the Menin Inhibitor Ziftomenib Wi
 th Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leuk
 emia\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06448013
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177079-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07177079)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: High-dos
 e Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Ven
 etoclax in Acute Myeloid Leukemia (AML)\nEstimated primary completion: 31 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/veneto
 clax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07177079
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06397027-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06397027)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: A Phase I Study Investigating the
  Combination of the Ziftomenib\, Venetoclax and Azacitidine in Pediatric R
 elapsed and Refractory Acute Leukemias\nEstimated primary completion: 31 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06397027
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191978-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT06191978)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 
 Ia/Ib Open-label\, Multiple Dose\, Study to Determine the Recommended Dose
 \, Evaluate PKs\, PDs\, Safety\, and Activity of Venetoclax in Combination
  With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Re
 lapsed/Refractory Acute Myeloid Leukemia (AML)\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06191978
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148180-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07148180)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Mult
 i-Site Break Through Cancer Trial: Targeting Measurable Residual Disease i
 n Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp\,
  Azacitidine\, and Venetoclax\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07148180
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317662-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06317662)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Testing the Addition of the Anti-
 cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab t
 o the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-
 rearranged or KMT2A-non-rearranged Leukemia\nEstimated primary completion:
  31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06317662
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05734495-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290125
DTEND;VALUE=DATE:20290126
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05734495)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Pirtobrutinib and Venetoclax in W
 aldenström Macroglobulinemia\nEstimated primary completion: 25 January 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05734495
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311746-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07311746)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Phase Ib/II Trial of Cladribine
 /Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolym
 phocytic Leukemia\nEstimated primary completion: 31 January 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07311746
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06084819-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06084819)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clinical
  Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relap
 sed/Refractory Acute Myeloid Leukemia\nEstimated primary completion: 31 Ja
 nuary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 084819
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423104-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07423104)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Cladribine\, Low Dose Cytarabine\, and Venetoclax in Treatment of Relap
 sed/Refractory or Secondary Acute Myeloid Leukemia\nEstimated primary comp
 letion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07423104
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407140-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07407140)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: VAG Vers
 us Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-M
 utated AML\nEstimated primary completion: 1 February 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07407140
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05791409-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05791409)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Venetoclax Treatment (26 Cycles
 ) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or R
 efractory CLL or SLL\nEstimated primary completion: March 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05791409
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04628026-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04628026)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Phase II
 I Study of Induction and Consolidation Chemotherapy With Venetoclax in Pat
 ients With Newly Diagnosed AML or MDS-EB-2\nEstimated primary completion: 
 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocla
 x#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 628026
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782542-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06782542)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Olutasid
 enib\, Venetoclax\, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute 
 Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy\nE
 stimated primary completion: 31 March 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06782542
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696183-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06696183)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilterit
 inib in Combination With Venetoclax and Azacitidine for AML Patients With 
 FLT3 Mutations Ineligible for Intensive Treatment\nEstimated primary compl
 etion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06696183
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582159-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07582159)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ta
 fasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic L
 ymphocytic Leukemia/Small Lymphocytic Lymphoma\nEstimated primary completi
 on: 14 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07582159
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05807932-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05807932)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Veneto
 clax in Addition to Sequential Conditioning With Fludarabine / Amsacrine /
  Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantatio
 n in Patients With MDS\, CMML or sAML\nEstimated primary completion: 30 Ap
 ril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0580
 7932
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023588-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07023588)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Study on
  Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on
  Early Peripheral Blood Minimal Residual Disease\nEstimated primary comple
 tion: May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venet
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07023588
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024706-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07024706)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: MA
 VRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relaps
 ed After a Course of BTKi + BCL2i Combination\, With or Without Obinutuzum
 ab\nEstimated primary completion: 1 May 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07024706
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMAT
 CH: A Screening Study to Assign People With Myeloid Cancer to a Treatment 
 Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screenin
 g Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317649-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06317649)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Mye
 loid Leukemia (AML) (A MyeloMATCH Treatment Trial)\nEstimated primary comp
 letion: 15 May 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06317649
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07635485-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Venetoclax: Phase na readout est. (NCT07635485)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: VA Indu
 ction and Bridging Transplantation for Hypoplastic/Secondary AML\nEstimate
 d primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07635485
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014462-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07014462)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 
 1B Investigator Initiated Study of Safety and Tolerability of Dexamethason
 e (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in 
 Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML\nEstimated primary
  completion: June 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07014462
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218510-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290608
DTEND;VALUE=DATE:20290609
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07218510)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ve
 netoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Unt
 reated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma\, LonGE
 Vity Trial\nEstimated primary completion: 8 June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07218510
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228273-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290624
DTEND;VALUE=DATE:20290625
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07228273)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Inductio
 n and Consolidation With Fludarabine\, Cytarabine\, Idarubicin\, and Venet
 oclax for the Treatment of Acute Myeloid Leukemia\nEstimated primary compl
 etion: 24 June 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07228273
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047183-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07047183)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Clinical Study of Venetoclax Comb
 ined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell
  Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes\nE
 stimated primary completion: 30 June 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07047183
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762508-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Venetoclax: Phase na readout est. (NCT07762508)
DESCRIPTION:Venetoclax\, phase na\, Acute Myeloid Leukemia.\nStudy: A Study
  of VABu Conditioning Regimen in Allo-HSCT for AML Patients\nEstimated pri
 mary completion: July 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07762508
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719556-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07719556)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Orelabrutinib Combined With Obinu
 tuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mant
 le Cell Lymphoma (MCL)\nEstimated primary completion: 1 July 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07719556
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03868722-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT03868722)
DESCRIPTION:Venetoclax\, phase 2/3.\nStudy: Acalabrutinib and Venetoclax Tr
 eatment of Newly Diagnosed Patients With CLL at High Risk of Infection or 
 Early Treatment\nEstimated primary completion: 31 July 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03868722
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691047-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Venetoclax: Phase na readout est. (NCT07691047)
DESCRIPTION:Venetoclax\, phase na\, Chronic Lymphocytic Leukemia.\nStudy: R
 eassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lym
 phocytic Leukemia Treated With a Regimen Containing Venetoclax\nEstimated 
 primary completion: 31 July 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07691047
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511062-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07511062)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Axatilim
 ab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated A
 ML\nEstimated primary completion: 1 August 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07511062
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471946-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06471946)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: VA Conditioning Regimen Allo-HS
 CT for Elderly Higher-risk MDS\nEstimated primary completion: 1 September 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06471946
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754799-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07754799)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Random
 ized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acut
 e Myeloid Leukemia\nEstimated primary completion: 30 September 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07754799
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755202-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07755202)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Gilterit
 inib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/
 Refractory Leukemia\nEstimated primary completion: 1 October 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07755202
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154264-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07154264)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)\nEstimated primary co
 mpletion: December 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07154264
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522801-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07522801)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: A Precision Medicine Trial for Pa
 tients With Relapsed or Refractory T Cell ALL\nEstimated primary completio
 n: 1 December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 enetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07522801
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690891-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07690891)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ne
 mtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymp
 hocytic Leukemia\nEstimated primary completion: 1 December 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07690891
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910801-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05910801)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Tafasitamab\, Lenalidomide and Ve
 netoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma\
 nEstimated primary completion: 30 December 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05910801
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513129-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07513129)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Venetoclax\, Dexamethasone\, Bort
 ezomib\, and Daratumumab For The Treatment Of Adolescent And Young Adults 
 With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell
  Acute Lymphoblastic Lymphoma\nEstimated primary completion: 31 December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07513129
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926607-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07926607)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Palboc
 iclib\, All-Trans Retinoic Acid\, and Venetoclax in Relapsed or Refractory
  Acute Myeloid Leukemia\nEstimated primary completion: 31 December 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07926607
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738887-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07738887)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ep
 coritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocy
 tic Leukemia With TP53 Alterations\nEstimated primary completion: 31 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0773
 8887
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561074-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06561074)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: A Phase 2 Study to Evaluate Effic
 acy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in 
 Pediatric\, Adolescent\, and Young Adult Patients With Relapsed/Refractory
  T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lym
 phoma (T-LLy)\nEstimated primary completion: 31 December 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06561074
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 
 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subje
 cts With R/R AML\nEstimated primary completion: 31 December 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764238-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT06764238)
DESCRIPTION:Venetoclax\, phase 2/3.\nStudy: Newly-diagnosed Intermediate/Hi
 gh Risk Pediatric B-cell ALL Protocol\nEstimated primary completion: 31 De
 cember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6764238
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481175-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07481175)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Inhibiting the Anti-apoptotic Fac
 tor\, BCL-2\, at the Time of ART Initiation to Promote Apoptosis of HIV-in
 fected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE S
 tudy)\nEstimated primary completion: January 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07481175
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07396480-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07396480)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Fludarab
 ine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan 
 Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantatio
 n in AML/MDS Patients Aged > 50 Years: a Multicenter\, Randomized\, Phase 
 3 Trial\nEstimated primary completion: 31 January 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07396480
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972641-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT06972641)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Molecu
 lar Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic 
 Stem Cell Transplantation\nEstimated primary completion: 31 March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06972641
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735184-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05735184)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study 
 to Investigate the Safety and Tolerability of Ziftomenib in Combination Wi
 th Venetoclax/Azacitidine\, Venetoclax\, 7+3\, or 7+3+Quizartinib in Patie
 nts With AML\nEstimated primary completion: April 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05735184
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07478991-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07478991)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Azacytid
 ine\, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Pat
 ients (VENP-A-QUI)\nEstimated primary completion: April 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07478991
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539818-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07539818)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Azacitid
 ine + Venetoclax VS Azacitidineas Maintenance Therapy in AML\nEstimated pr
 imary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07539818
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06991920-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Venetoclax: Phase na readout est. (NCT06991920)
DESCRIPTION:Venetoclax\, phase na.\nStudy: Immune-targeted Combination With
  Chemotherapy for Acute Leukemia of Ambiguous Lineage\nEstimated primary c
 ompletion: 1 April 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06991920
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153497-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07153497)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 the Use of an IDH1 Inhibitor\, Olutasidenib\, in Acute Myeloid Leukemia Ad
 ded to ASTX727 and Venetoclax\; in High-Risk MDS Added to ASTX727\; and Al
 one in Low Risk MDS (A MyeloMATCH Treatment Substudy)\nEstimated primary c
 ompletion: 26 April 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07153497
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02115295-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02115295)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Cladribi
 ne\, Idarubicin\, Cytarabine\, and Venetoclax in Treating Patients With Ac
 ute Myeloid Leukemia\, High-Risk Myelodysplastic Syndrome\, or Blastic Pha
 se Chronic Myeloid Leukemia\nEstimated primary completion: 31 May 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02115295
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07078591-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07078591)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax-containing Therapy Combined With Microtransplant for Newly Diagnosed AM
 L\nEstimated primary completion: June 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07078591
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07238686-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07238686)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Venetoclax-containing Therapy Com
 bined With Microtransplant for Intermediate-risk and Higher MDS\nEstimated
  primary completion: June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07238686
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855810-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT06855810)
DESCRIPTION:Venetoclax\, phase 2/3.\nStudy: Newly-diagnosed Pediatric T-cel
 l ALL Protocol\nEstimated primary completion: June 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06855810
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810778-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT06810778)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: Duvelisib and Venetoclax in Pat
 ients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)\nEstim
 ated primary completion: 1 June 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06810778
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672262-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07672262)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA Conso
 lidation in Intermediate-Risk AML\nEstimated primary completion: 1 June 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07672262
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320235-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300617
DTEND;VALUE=DATE:20300618
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07320235)
DESCRIPTION:Venetoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Imetelst
 at Combinations in Relapsed AML\nEstimated primary completion: 17 June 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07320235
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520098-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06520098)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or With
 out Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small L
 ymphocytic Lymphoma (SLL)\nEstimated primary completion: 30 June 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06520098
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05442216-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300721
DTEND;VALUE=DATE:20300722
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05442216)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Tagraxof
 usp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After
  Hypomethylating Agents\nEstimated primary completion: 21 July 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05442216
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07713732-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300829
DTEND;VALUE=DATE:20300830
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07713732)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: TLN-499 in Combination With Venet
 oclax in Patients With Relapsed/Refractory Solid Tumors\nEstimated primary
  completion: 29 August 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07713732
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06598384-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06598384)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: VA as Ma
 intenance Therapy Post Allo-HSCT in MDS and AML\nEstimated primary complet
 ion: September 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06598384
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05904106-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05904106)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetocl
 ax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Ne
 wly Diagnosed NPM1 Mutated AML\nEstimated primary completion: September 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05904106
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082452-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07082452)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Multic
 enter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposur
 e To Seven Days Versus Standard Continuous Venetoclax Exposure Combined Wi
 th Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Wh
 o Are Ineligible for Intensive Induction\nEstimated primary completion: Se
 ptember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07082452
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358195-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Venetoclax: Phase 1 readout est. (NCT07358195)
DESCRIPTION:Venetoclax\, phase 1.\nStudy: Addition of Venetoclax to Combine
 d Hematopoietic Stem Cell and Kidney Transplantation\nEstimated primary co
 mpletion: December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07358195
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02966756-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02966756)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Venetoclax in Participants With Relapsed or Refractory Chronic Ly
 mphocytic Leukemia/Small Lymphocytic Lymphoma\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ven
 etoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02966756
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554419-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05554419)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing 
 the Use of Combination Therapy in Patients With Persistent Low Level Acute
  Myeloid Leukemia Following Initial Treatment\, The ERASE Study (A MyeloMA
 TCH Treatment Trial)\nEstimated primary completion: 31 December 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05554419
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05091424-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20310210
DTEND;VALUE=DATE:20310211
SUMMARY:Venetoclax: Phase 1 readout est. (NCT05091424)
DESCRIPTION:Venetoclax\, phase 1\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study Evaluating the Safety\, Efficacy\, and Pharmacokinetics of Mosunetuz
 umab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participant
 s With Relapsed or Refractory Chronic Lymphocytic Leukemia\nEstimated prim
 ary completion: 10 February 2031. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05091424
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03314181-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03314181)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: A Study of Com
 bination Therapy With Venetoclax\, Daratumumab and Dexamethasone (With and
  Without Bortezomib) in Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: May 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03314181
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967610-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Venetoclax: Phase 2 readout est. (NCT06967610)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: Ph
 ase II Study of Combined Pirtobrutinib\, Venetoclax and Obinutuzumab (PVO)
  Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Le
 ukemia/Small Lymphocytic Lymphoma (CLL/SLL).\nEstimated primary completion
 : 1 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/veneto
 clax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06967610
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604233-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20310603
DTEND;VALUE=DATE:20310604
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07604233)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase 
 1/2 FLAG-IDA\, VEN and Asciminib in CML and Ph+ AML\nEstimated primary com
 pletion: 3 June 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07604233
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431257-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20310901
DTEND;VALUE=DATE:20310902
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05431257)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Azacitid
 ine in Combination With Low Dose Intensity Venetoclax in Patients With AML
  Incl. Explorative AML Profiling\nEstimated primary completion: 1 Septembe
 r 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054312
 57
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710534-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07710534)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Metronom
 ic Decitabine-Cedazuridine and Venetoclax in R/R AML\, HR-MDS\, HR/AP MPN\
 nEstimated primary completion: 30 September 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07710534
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175415-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20311001
DTEND;VALUE=DATE:20311002
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07175415)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: HEM-iSMART E: Capivasertib + Ve
 netoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory
  Hematological Malignancies\nEstimated primary completion: 1 October 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07175415
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007312-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07007312)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Studies 
 to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With U
 ntreated NPM1-m or KMT2A-r AML\nEstimated primary completion: November 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007312
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745714-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05745714)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: HEM-iSMART-C: Ruxolitinib + Ven
 etoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Pat
 ients With Relapsed or Refractory Hematological Malignancies\nEstimated pr
 imary completion: 1 February 2032. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05745714
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05751044-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05751044)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: HEM-iSMART-B: Dasatinib + Venet
 oclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patie
 nts With Relapsed or Refractory Hematological Malignancies\nEstimated prim
 ary completion: 1 February 2032. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05751044
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294677-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07294677)
DESCRIPTION:Venetoclax\, phase 1/2.\nStudy: CApivasertib\, Venetoclax And L
 ow-intensity chemotheRapY for Adults With ALL/LBL\nEstimated primary compl
 etion: March 2032. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ve
 netoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07294677
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581002-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07581002)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stud
 y to Assess Adverse Events and Change in Disease Activity When Intravenous
  (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and 
 IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Le
 ukemia (AML)\nEstimated primary completion: June 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07581002
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05947851-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20320601
DTEND;VALUE=DATE:20320602
SUMMARY:Venetoclax: Phase 3 readout est. (NCT05947851)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in S
 econd-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/S
 mall Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).\nEstimated
  primary completion: 1 June 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05947851
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Study 
 of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primary 
 completion: December 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03013998
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520006-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20330531
DTEND;VALUE=DATE:20330601
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT07520006)
DESCRIPTION:Venetoclax\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of NX-5948 in Combination With Other Agents in Adults With B-cell Ma
 lignancies\nEstimated primary completion: May 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07520006
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07437950-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20340922
DTEND;VALUE=DATE:20340923
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07437950)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: Comparin
 g Different Treatment Lengths for Venetoclax in Older People With Newly Di
 agnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)\nEstimated p
 rimary completion: 22 September 2034. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07437950
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948122-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Venetoclax: Phase 3 readout est. (NCT07948122)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: Prospect
 ive Evaluation of Response to Treatment in Younger Adult Patients (18-60 Y
 ears) With Acute Myeloid Leukemia (AML)\nEstimated primary completion: 31 
 December 2035. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/veneto
 clax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07948122
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Study to Investigate Outcome of I
 ndividualized Treatment in Patients With Metastatic Colorectal Cancer\nEst
 imated primary completion: 31 December 2038. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02689440-2078@assetmemo.bio
DTSTAMP:20261121T004952Z
DTSTART;VALUE=DATE:20401231
DTEND;VALUE=DATE:20410101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02689440)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Dasatinib and Venetoclax in Treat
 ing Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Ea
 rly Chronic Phase Chronic Myelogenous Leukemia\nEstimated primary completi
 on: 31 December 2040. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT02689440
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
